The market access “sweet spots” where payers reimburse more convenient therapies

U.S. payers often say they “don’t pay for convenience,” yet across several therapeutic areas, long-acting injectables (LAIs) command premium prices and broad coverage. In areas like HIV prevention and opioid use disorder, coverage decisions are heavily shaped by policy and federal mandates. These are therapeutic areas where payer leverage is more limited. It’s important not to assume the same dynamics will apply to your therapeutic area.

Case Study 1: HIV Pre-Exposure Prophylaxis (APRETUDE vs. generic daily oral TDF/FTC)

APRETUDE is a long-acting injectable for HIV pre-exposure prophylaxis (PrEP). Its annual list price is about $25,000 per year—roughly 70 times higher than generic oral TDF/FTC. Despite the price gap, payers cover APRETUDE on par with oral generic options due to federal mandates.

Under the Affordable Care Act (ACA), PrEP is designated a U.S. Preventive Services Task Force (USPSTF) Grade A service.^[1] This requires most commercial and ACA health plans to cover all FDA-approved PrEP products – including APRETUDE – with zero cost-sharing.^[2] Plans cannot impose step therapy, prior authorization, or adherence-based restrictions. As a result, APRETUDE is reimbursed at its established price under the mandate, independent of payer preference.

Case Study 2: Opioid Use Disorder (SUBLOCADE and BRIXADI vs. Generic Daily Orals)

Long-acting buprenorphine injectables SUBLOCADE (monthly) and BRIXADI (weekly or monthly) have an annual list price of $20,000–$25,000, versus about $1,000 annual list price for daily generic buprenorphine. Despite the price gap, Medicaid must cover all FDA-approved medications for opioid use disorder under the SUPPORT Act (2018).^[3] According to Clarivate Fingertip Formulary data, SUBLOCADE and BRIXADI have achieved over 99% coverage across commercial, Medicare Advantage, and Medicaid plans that include both pharmacy and medical benefits.

Conclusion

Across HIV and opioid use disorder, long-acting injectables (LAIs) often achieve higher prices and broad coverage because payers have limited leverage in these therapeutic areas. These represent “sweet spots” where payers are largely hands-off and coverage is policy-driven. Looking ahead, value frameworks should clearly differentiate between adherence-driven benefits and policy-mandated coverage to better reflect true payer decision dynamics.

 Clarivate’s experienced market access and pricing experts can help you analyze, optimize, and tailor your strategy to maximize commercial success. Visit us to learn more or connect with our experts: Healthcare Commercial Consulting Services | Clarivate

[1] USPSTF recommendation of Grade A for PrEP. Link

[2] KFF Preventive Services Covered by Private Health Plans under the Affordable Care Act. Link

[3] CMS Guidance about Expanded Medicaid Coverage for Treatment of Opioid Use Disorders. Link

Biopharma Commercialization Consulting Resource Center FDA HMO Launch Managed care Market Access MCO North America Payer PBM pricing Route of administration U.S.

content_copy Copy link Copied